Anlotinib Recruiting Phase 2 Trials for Soft Tissue Sarcoma (STS) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03890068Anlotinib Hydrochloride for Soft Tissue Sarcoma Patients.
NCT03815474Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients